Industry News

May 19, 2012

Discovery Alters Prevailing View Of Splicing Regulation And Has Implications For Splicing Mutations Associated With Disease

There are always exceptions to a rule, even one that has prevailed for more than three decades, as demonstrated by a Cold Spring Harbor Laboratory (CSHL) study on RNA splicing, a cellular editing process... Read More
May 18, 2012

Hormone-Depleting Drug Shows Promise Against Localized High-Risk Prostate Tumors

A hormone-depleting drug approved last year for the treatment of metastatic prostate cancer can help eliminate or nearly eliminate tumors in many patients with aggressive cancers that have yet to spread beyond the prostate, according to a clinical study to be presented at the annual meeting of the American Society of Clinical Oncology (ASCO), June 1-5, in Chicago... Read More
May 18, 2012

New National Guidelines For Treatment Of Subarachnoid Hemorrhage

People with bleeding brain aneurysms have the best chance of survival and full recovery if they receive aggressive emergency treatment from a specialized team at a hospital that treats a large number of patients like them every year, according to new guidelines just published by the American Stroke Association... Read More
May 17, 2012

Trial Of ALK Inhibitor In Neuroblastoma, Lymphoma

A pill designed to zero in on abnormal genes that drive specific cancers has produced encouraging early results in children with an uncommon but aggressive type of lymphoma, as well as in children with a rare form of neuroblastoma... Read More
May 17, 2012

Older People With Chronic Leukemia May Benefit From Experimental Agent

The experimental drug ibrutinib (PCI-32765) shows great promise for the treatment of elderly patients with chronic lymphocytic leukemia (CLL), according to interim findings from a clinical trial. The phase I/II trial, co-led by researchers at the Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J... Read More
May 17, 2012

Personalized Treatment Advances: Testing For Mutations Identified In Squamous Cell Lung Cancer Tumors

Screening lung cancer tumor samples for cancer-causing, or "driver," genetic mutations can help physicians tailor patients' treatments to target those specific mutations... Read More
May 17, 2012

Patients With Muscle-Invasive Bladder Cancer Benefit From Accelerated Chemotherapy Given Before Surgery

For some patients with muscle-invasive bladder cancer, treatment may begin before they undergo cystectomy, or surgical removal of the bladder. They may be advised by oncologists to receive chemotherapy before surgery... Read More
May 17, 2012

Glioblastoma Classification Revision Should Improve Patient Care

Radiation oncology researchers have revised the system used by doctors since the 1990s to determine the prognosis of people with glioblastoma, which is the most devastating of malignant brain tumors. The outdated system was devised for glioblastoma and related brain tumors that were treated by radiation therapy only, and it relied on clinical signs and symptoms... Read More
May 17, 2012

Minimal Residual Disease Detected In Nearly Double The Number Of Leukemia Patients Using High-Throughput Sequencing

A study led by researchers at Fred Hutchinson Cancer Research Center has found that a next-generation, high-speed DNA-decoding technology called high-throughput sequencing can detect the earliest signs of potential relapse in nearly twice the number of leukemia patients as compared to flow cytometry, the current gold standard for detecting minimal residual disease... Read More
May 17, 2012

The Cause Identified Of LGL Leukemia

LGL leukemia is a relatively rare, malignant blood disease of the mature T-cells and, in many cases, it is related to autoimmune diseases such as rheumatoid arthritis. The pathogenetic mechanism of the disease has been unknown and it has previously been unclear if the disease is an overreaction of the normal defense system or a malignant hematological disease... Read More
Next Page